This HTML5 document contains 198 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q36287555
rdf:type
wikibase:Item
schema:description
artigo científico articolo scientifico article scientific artigo científico (publicado na 2015) מאמר מדעי artículu científicu espublizáu en 2015 2015年學術文章 مقالهٔ علمی мақолаи илмӣ artykuł naukowy wetenschappelijk artikel naučni članak vědecký článek article scientifique (publié 2015) bài báo khoa học 2015年學術文章 scientific article գիտական հոդված 2015年學術文章 2015年學術文章 teaduslik artikkel 2015年学术文章 επιστημονικό άρθρο bilimsel makale artikulong pang-agham vitskapeleg artikkel 2015年學術文章 2015年学术文章 научна статия mokslinis straipsnis บทความทางวิทยาศาสตร์ videnskabelig artikel (udgivet 2015) 2015年学术文章 научни чланак artículo científico publicado en 2015 artigo científico (publicado na 2015) مقالة علمية نشرت بتاريخ 26-2-2015 wissenschaftlicher Artikel vedecký článok vitenskapelig artikkel article científic 2015년 논문 tudományos cikk სამეცნიერო სტატია научни чланак мақолаи илмӣ наукова стаття, опублікована в лютому 2015 ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2015年學術文章 artikull shkencor vetenskaplig artikel scienca artikolo 2015年学术文章 سائنسی مضمون articol științific tieteellinen artikkeli 2015年学术文章 научная статья 2015 nî lūn-bûn 2015年の論文
p:P577
wds:Q36287555-ED494988-495E-404B-9004-345255789D17
wdt:P577
2015-02-26T00:00:00Z
p:P2860
wds:Q36287555-ABCB0DBE-D79E-49BC-BA1D-DB3C57E52764 wds:Q36287555-9D6A996F-19C2-4AE2-AAF9-B0F7ECC95DBD wds:Q36287555-9E208EEF-01C5-4D64-BFC6-A2048FDE2ADB wds:Q36287555-8F128080-D51F-4D09-8DF7-A607861D5D4F wds:Q36287555-003D5617-DE14-4C18-8F67-019A70666A00 wds:Q36287555-01C83452-CD7D-4F2F-87B1-9270A3E49962 wds:Q36287555-36950970-06B5-42F5-879D-69D06F2206C8 wds:Q36287555-4142E5CE-FE58-469F-A60E-0D5A5A9963A9 wds:Q36287555-2D0BC045-6C5F-425A-AD28-2F911EA60110 wds:Q36287555-32350D78-5754-4794-A3D0-D68C9AA95BE4 wds:Q36287555-32A51946-0475-464D-800C-D0CC4DBE1FCF wds:Q36287555-E967133A-36AD-45F1-A9AF-BC274053B17C wds:Q36287555-D2C75628-9121-4933-B3E1-5E2514FB40D2 wds:Q36287555-D500D326-DBE4-4F1C-9B5A-E469CCE0D119 wds:Q36287555-BA4EB13B-A430-4041-A571-EE85E7441290 wds:Q36287555-C4D97E55-3AAE-4891-8DB2-71B9183F0BC5 wds:Q36287555-6A9470A5-6E5D-434C-B4F3-619995CEF535 wds:Q36287555-81E85B85-5C4E-4DD0-8208-08B04EC406BE wds:Q36287555-520086AD-8E9D-4B17-B17B-3162EBEDF7C0 wds:Q36287555-5DF2AE38-9989-4CF7-BCAC-5E9DEB07FAF4 wds:Q36287555-60BDEAC1-4B4D-47E8-9DD6-D131E94178DC wds:Q36287555-4D553E68-6993-4074-ACC7-5DCD0360B153 wds:Q36287555-51C96CDB-B6AE-477C-9759-B5CCDA298E08 wds:Q36287555-AF82A521-2E24-4997-BB6A-0B1754C36759 wds:Q36287555-B5A6DA08-41CB-4082-84D4-B96CC99FF470 wds:Q36287555-A4046136-2893-47DB-A3CF-81F62D6785A1
wdt:P2860
wd:Q37996276 wd:Q36599355 wd:Q38447094 wd:Q51998139 wd:Q24647137 wd:Q34338450 wd:Q33807147 wd:Q43179227 wd:Q54467711 wd:Q37274874 wd:Q33430265 wd:Q38171263 wd:Q29620144 wd:Q28383049 wd:Q34349749 wd:Q57203122 wd:Q36815449 wd:Q34514165 wd:Q34605490 wd:Q34361636 wd:Q26782022 wd:Q34259027 wd:Q34519039 wd:Q28742450 wd:Q40180199 wd:Q45722508
p:P2093
wds:Q36287555-37966019-B477-41BA-A249-76BA4495B606 wds:Q36287555-0CD04D47-477A-4E1B-BD31-422C3BFE2339 wds:Q36287555-11731AF6-D369-4B11-8E05-56552B71CD3D wds:Q36287555-18E07B69-42B5-46FB-B254-A41B98ED8F61 wds:Q36287555-B3195B64-DA5B-4D22-AABF-FF261CD1D759 wds:Q36287555-8E57B22F-268D-40A7-80BF-8882FD6CF3A7 wds:Q36287555-A0FB2AE3-69E7-4C46-8AB7-A9B0D89A86DC wds:Q36287555-64D86AC3-EE85-4450-952B-3962BA6886A1 wds:Q36287555-8AFBA40F-5C86-4953-B695-C64AE04B1BAA wds:Q36287555-4D53FB2C-B4A1-4D64-AB7D-0CB5FCF989C8 wds:Q36287555-E32A556B-20D6-43DC-9AE5-11F61807F35B wds:Q36287555-CDDE6A13-A3B6-4681-A2F7-97C769A77633 wds:Q36287555-CF247176-DC34-4589-8F6C-729C42F93EE8
wdt:P2093
Michael Raine MVA85A 030 trial investigators Marta Romano Iman Satti Ibrahima Ndiaye Rene Goliath Vanessa January Aminata Thiam Tandakha Ndiaye Dieye Sharon Sutton Martin Ota Siry Dièye Bernard S Landry
rdfs:label
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
skos:prefLabel
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
schema:name
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
p:P50
wds:Q36287555-D55CC1FD-967B-4DEE-BE0B-0941C7EEDEBB wds:Q36287555-DC174DC5-866B-400D-A6BB-C6A88ED730ED wds:Q36287555-F0200C59-1D46-45B9-8497-BC220960DB84 wds:Q36287555-9952E0E7-C34C-4197-8728-09CC6C25FEE4 wds:Q36287555-A0489DD9-AFF4-48E8-AE33-11F6CBF85A03 wds:Q36287555-A9DF91D1-83A4-4550-9894-81961590B3D9 wds:Q36287555-46B9D301-6AC0-4BE7-8CB1-EFF24CEE0BC5 wds:Q36287555-8E0E1C86-96ED-478F-B769-CB9E1FFC895A wds:Q36287555-08F5724D-C26C-4560-9735-5AF353B3893E wds:Q36287555-0AE56433-DE01-4A0A-A992-B847C3C19624
wdt:P50
wd:Q86910301 wd:Q125341780 wd:Q32072525 wd:Q56441710 wd:Q58870907 wd:Q3491657 wd:Q55523569 wd:Q30423489 wd:Q125341726 wd:Q57055698
p:P1476
wds:Q36287555-A563993F-B61D-4914-84D0-BD973A6AD319
wdt:P1476
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
p:P304
wds:Q36287555-940FE912-6387-4670-85CF-A4BC2EB3D913
wdt:P304
190-200
p:P31
wds:Q36287555-7946AA24-7621-410A-AFD9-6A186101E185
wdt:P31
wd:Q13442814
p:P921
wds:Q36287555-16A39D8E-5D36-4A18-B914-5106D6E7DBBB wds:Q36287555-39B65D34-5441-4A52-8716-791BE0A741B1 wds:Q36287555-576A230A-425F-427C-A25F-5453BD1288FD wds:Q36287555-B181D8DA-CC44-460C-B597-C01357780346
wdt:P921
wd:Q12204 wd:Q42824440 wd:Q15787 wd:Q269829
p:P698
wds:Q36287555-1B32355F-C8E0-4FCB-8793-108C7411670F
wdtn:P698
n12:25726088
wdt:P698
25726088
p:P1433
wds:Q36287555-89812F08-F573-48C6-A574-C0CB052913BB
wdt:P1433
wd:Q27724908
p:P433
wds:Q36287555-13D06448-B070-4D84-A5D5-5187900BA714
p:P478
wds:Q36287555-BD8D5301-B2FA-430E-A508-9B87F89092C2
wdt:P433
3
wdt:P478
3
p:P356
wds:Q36287555-1FC06000-A875-4EBD-A96D-11AC25F629F1
wdtn:P356
n10:S2213-2600(15)00037-5
wdt:P356
10.1016/S2213-2600(15)00037-5
p:P932
wds:Q36287555-8451A0EC-0702-4C72-9F60-47100E41FB53
wdt:P932
4648060